



Biogroup Announces Chief Financial Officer Transition

Levallois-Perret, September 10, 2024

Biogroup, today announced that Chief Financial Officer Rémy Fassin will be stepping down from his role. Mrs Anne-France Laclide will succeed him as Chief Financial Officer and join the executive team. Rémy Fassin will remain with Biogroup through the end of September 2024 to ensure a smooth transition.

“I want to thank Rémy for his many contributions to Biogroup. He has been a great CFO and partner whose total commitment was over the past 3 years, which have been restless for the company, and before when he structured Laborizon for several years before its integration into Biogroup,” said Isabelle Eimer, Chairman of Biogroup.

“I am very excited to welcome Anne-France to her new role. She is an excellent addition to our leadership team given her deep experience and track record of financial leadership for international companies,” mentioned Frédéric Dauche, CEO of Biogroup.

“I am incredibly honored to have worked at Biogroup and proud of what both the company and the finance organization have accomplished,” said Rémy Fassin. “I am confident in Anne-France’s ability to lead our financial strategy and continue driving our success.”

Mrs Anne-France Laclide brings years of experience in financial leadership roles, having previously held senior CFO positions at Ingenico, RATP Dev, Oberthur Technologies and Elis.

“I am thrilled to take on this new role during such an exciting time of growth and transformation,” said Anne-France Laclide. “I look forward to partnering with the executive committee as the transformation plan is now on track in a challenging regulatory environment and I am impatient to meet our financial debt investor community.”

Consequently, the Group will delay its detailed presentation, initially scheduled during a Capital Market Day early September, of its transformation plan, strategy, and performance and will plan a new date to present it to its financial investors.

About Biogroup

Biogroup is the leading player in medical lab testing in France and Belgium with a revenue of €1.5bn. Majority-owned by the French and Belgian shareholders, Family Eimer and Straco respectively, Biogroup operates close to 1,000 labs located in France, Belgium, Luxembourg and Spain.